As of March 7, 2024, Biokin Pharmaceutical has received an initial payment of USD 800 million from Bristol Myers Squibb under the development and commercialization license agreement for BL-B01D1.

Agreement Signing and EffectivenessOn December 11, 2023, SystImmune, Inc., a wholly-owned subsidiary of Biokin Pharmaceutical, entered into an exclusive licensing and collaboration agreement (hereinafter referred to as the "Collaboration Agreement") with Bristol Myers Squibb (hereinafter referred to as "BMS", NYSE ticker: BMY) pertaining to the BL-B01D1 (EGFR×HER3 bispecific ADC) project. Under the terms of the Agreement, the Parties will jointly pursue the development and commercialization of BL-B01D1 in the United States. SystImmune will exclusively be responsible for the development, commercialization, and production of BL-B01D1 within Chinese mainland through its affiliated entities, including manufacturing some drugs for supply to regions outside of Chinese mainland. Conversely, BMS will retain exclusive right to develop and commercialize BL-B01D1 in all other regions globally. The Collaboration Agreement officially took effect on February 8, 2024.

Regarding BL-B01D1 (EGFR×HER3 Bispecific ADC)

BL-B01D1 is an Antibody-Drug Conjugate (ADC) that utilizes bispecific topoisomerase inhibitors to simultaneously target epidermal growth factor receptor and human epidermal growth factor receptor 3 (EGFRxHER3). Presently, a global multicenter Phase I clinical study (BL-B01D1-LUNG101) is underway to assess its safety and effectiveness in patients with metastatic or unresectable non-small cell lung cancer (NSCLC).

About SystImmune, Inc.

SystImmune is a clinical-stage biopharmaceutical company headquartered in Redmond, Washington. The company is dedicated to harnessing its well-established drug development platform to develop innovative cancer therapies, with a focus on the research and development of bispecific, multispecific antibodies, and antibody-drug conjugates (ADCs). For more information, please visit systimmune.com.

http://en.baili-pharm.com/newsshow.aspx?mid=18&id=2119